BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 24177197)

  • 21. Urinary Biomarkers for Prostate Cancer.
    Giunchi F; Ciccarese C; Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L; Moch H; Massari F; Fiorentino M
    Curr Drug Metab; 2017 Oct; 18(8):723-726. PubMed ID: 28524004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of current biomarkers for prostate cancer detection.
    Kim JH; Hong SK
    Investig Clin Urol; 2021 Jan; 62(1):1-13. PubMed ID: 33381926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer.
    Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS
    Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll PR; Feng Z; Gleave ME; Lance RS; Sanda MG; Thompson IM; Wei JT; Nelson PS;
    Clin Cancer Res; 2013 May; 19(9):2442-50. PubMed ID: 23515404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
    Schmid M; Hansen J; Chun FK
    Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes.
    Hendriks RJ; Dijkstra S; Jannink SA; Steffens MG; van Oort IM; Mulders PF; Schalken JA
    Clin Chem Lab Med; 2016 Mar; 54(3):483-92. PubMed ID: 26630694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond prostate-specific antigen - future biomarkers for the early detection and management of prostate cancer.
    Killick E; Bancroft E; Kote-Jarai Z; Eeles R
    Clin Oncol (R Coll Radiol); 2012 Oct; 24(8):545-55. PubMed ID: 22682955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
    Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
    Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
    Mengual L; Lozano JJ; Ingelmo-Torres M; Izquierdo L; Musquera M; Ribal MJ; Alcaraz A
    BMC Cancer; 2016 Feb; 16():76. PubMed ID: 26856686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.
    Nilsson J; Skog J; Nordstrand A; Baranov V; Mincheva-Nilsson L; Breakefield XO; Widmark A
    Br J Cancer; 2009 May; 100(10):1603-7. PubMed ID: 19401683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New biomarkers in serum and urine for detection of prostate cancer].
    Stephan C; Jung K; Miller K; Ralla B
    Aktuelle Urol; 2015 Mar; 46(2):129-43. PubMed ID: 25897535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An up-to-date catalogue of urinary markers for the management of prostate cancer.
    Brönimann S; Pradere B; Karakiewicz P; Huebner NA; Briganti A; Shariat SF
    Curr Opin Urol; 2020 Sep; 30(5):684-688. PubMed ID: 32701725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
    Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
    Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
    Salagierski M; Schalken JA
    J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Mix-to-Go" Silver Colloidal Strategy for Prostate Cancer Molecular Profiling and Risk Prediction.
    Wang J; Koo KM; Wang Y; Trau M
    Anal Chem; 2018 Nov; 90(21):12698-12705. PubMed ID: 30260630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.